A Publication for the Practising Medical Specialist, Industry Executive

Medical Device News Magazine delivers the latest updates from the medical device and biotechnology sectors. 

Stay Ahead in Medical Technology

At Medical Device News Magazine, we take pride in delivering high-quality, in-depth news. Our content goes beyond the surface, providing a comprehensive look at the trends, innovations, and breakthroughs that are shaping the future of medical technology.

In addition, we aim to offer a unique perspective on the rapidly evolving healthcare landscape. By following our news, you gain exclusive insights into industry developments, emerging technologies, and regulatory updates that impact medical devices worldwide. At the same time, you become part of a vibrant community of professionals, innovators, and thought leaders who are dedicated to advancing healthcare through cutting-edge solutions.

Furthermore, we encourage you to explore our diverse range of content, from the latest product announcements to in-depth analyses of industry trends. If our vision aligns with your objectives, we also offer opportunities for advertising and collaboration, allowing you to reach a highly engaged audience of medical technology professionals.

Stay informed, stay connected, and join us as we navigate the future of healthcare together.

Medical Device Industry News: Latest Developments, Breakthroughs, and Future Outlook

Clinical Trials

NFL Alumni Joel Dreessen and Le-Lo Lang Team Up With HeartFlow and Boone Heart Institute to Launch GAMEFILM Registry to Assess Heart Disease Risks in Retired Football Players

The GAMEFILM Registry will enroll approximately 120 NFL alumni. The Registry will leverage coronary computed tomography angiography (CCTA) imaging and insights from the HeartFlow ONE platform (HeartFlow FFRCT and Plaque Analysis) to collect observational data with the goal of better understanding CAD prevalence, risk factors, severity, and treatment protocols among retired athletes.

Biotechnology News

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

Guido Baechler, CEO of Mainz Biomed: “Securing the exclusive rights to license this portfolio of novel biomarkers is a major milestone and extension of our previously announced PancAlert program. It provides us with an extraordinary opportunity in the early detection and diagnosis of one of the most challenging cancers to treat. We believe that this achievement marks a paradigm shift in how we can detect pancreatic cancer.”

Medigene Submits Patent for Unique NK-Specific TCR Construct with European Patent Office

“This innovative approach supports our strategy to apply Medigene’s 3S TCRs into new TCR-guided modalities, such as TCR-TCEs and now TCR-NKs, to create additional value for both patients and our shareholders,” said Selwyn Ho, CEO of Medigene. “Expanding our TCR-guided therapies to include NK cells aligns with our commitment to developing off-the-shelf, highly specific, and effective immunotherapies for cancer treatment.”

Our Experts – Byline Articles

Read Their Views & Share With a Colleague or Two!

Applied Research

How Applied Research is Transforming Medical Device Startups | By Hannah Eherenfeldt, Co-founder & CEO of ReSuture

Medical device startups face numerous barriers when trying to penetrate the crowded startup landscape. Fundraising is highly competitive, and many products fail to reach the market due to insufficient funding for research, validation, and testing. The applied research model provides a solution.This industry expert notes this is where the applied research model comes in.

Executives on the Move

FDA Medical Device Updates

Comprehensive Insights into Medical Device & Biotechnology Company Mergers, Acquisitions & Funding

Ora Announces Strategic Investment from The Vistria Group to Propel Global Growth, Enhance Customer Experience in Ophthalmic Research

With this investment, The Vistria Group will support Ora as the globally preferred clinical research partner of ophthalmic innovators. It also marks The Vistria Group’s commitment to further supporting cutting-edge therapies and advancing diversity in specialized clinical research. Ora is the seventh company in The Vistria Group’s pharma services portfolio and underscores the firm’s continued focus on life sciences.

Market Reports

Advancements In Imaging

Insightec MR-Guided Focused Ultrasound Technology Recommended for National Coverage for Dutch Patients Living with Essential Tremor

According to an Insightec study, patients experienced significant reductions in upper limb tremor, tremor-related disability, and quality of life. The most common intraprocedural adverse events included dizziness, headache, nausea, and vomiting, which all resolved. Post-procedural adverse events included paraesthesia and gait disturbance, which were often transient or resolved within 12 months.

IVUS

Multidisciplinary Panel of Experts from Prominent Cardiovascular Societies Advocate for Broader Adoption of IVUS in Peripheral Interventions to Improve Patient Care

Chris Landon, Business Leader Image Guided Therapy Devices at Philips:
“IVUS is a technology that has demonstrated an ability to both support safer procedures for patients and procedural staff alike including reductions in radiation exposure. As the global leader in IVUS solutions, we are grateful for the rigorous multidisciplinary approach to developing expert consensus on the value of IVUS and we look forward to working with all stakeholders to standardize the use of IVUS and reduce the barriers preventing utilization.”

Hospitals In the News

Medical Device and Biotechnology Executives: Innovative Professionals on the Move and Making Waves in the Industry

Non-Profit News

Healthcare: Understanding the Business Side of the Industry and Its Implications

Healthcare Careers

Nurses Corner

Health: A Comprehensive Exploration of Wellness, Nutrition, and Overall Well-Being for a Healthier Life

Articles Designed to Inspire and Guide You Toward Achieving Excellence and Success in All Your Endeavors.